Mabruka Alfaidi, MD, PhD
Assistant Professor of Internal Medicine, Division of Cardiology
PhD in Cardiovascular Science from the University of Sheffield, UK
August 6-11, 2023
Dr. Alfaidi was invited to give an oral presentation in the "Young Investigators in Cardiovascular Biomechanics and Mechanobiomedicine" at the Biomechanics in Vascular Biology and Disease Gordon Research Conference, Mount Holyoke College, South Hadley, MA.
June 18-23, 2023
Dr. Alfaidi will be a Discussion Leader at the The Atherosclerosis Gordon Research Seminar (Insights into Successfully Obtaining Grants) in Barcelona, Spain.
The Alfaidi Lab officially opened!
Dr. Alfaidi was recruited to be one of the members of the ATVB Journal Digital Strategy Team.
Dr. Alfaidi won of the ATVB Investigator in Training Award.
Dr. AlfaidI won the British Atherosclerosis Society's Young Investigator Award.
Dr. Alfaidi served on the ATVB Early Career Editorial Board.
Intramolecular Pathway(s) of Unstable Atheroma in Coronary Artery Disease
Coronary artery disease (CAD) is a major health problem with co-morbidities and high mortality rates. Despite our advances, we still do not have a curative therapy to CAD. Atherosclerosis, an underlying progressive disease process, can rupture leading to the sudden death or acute myocardial infarction in CAD patients. The instability of coronary atheroma is largely characterized by high mesenchymal content, large necrotic cores, and more pro-inflammation. We previously have identified the major lesion culprit, interleukin-1 beta, in the endothelium of coronary atheroma in patients of CAD. This project aims at understanding the molecular function of endothelial-to-mesenchymal transition (EndMT), fate and their contribution to the lesion instability.
Endothelial cell remodeling in Idiopathic Pulmonary Hypertension
Idiopathic pulmonary arterial hypertension (IPAH) is increasingly diagnosed in elderly patients who have an increased risk of co-morbid atherosclerosis. Once diagnosed, the median survival rate is 2.5 years with poor prognostic outcomes. The underlying pathology in IPAH is very complex yet has very remarkable characteristics, including endothelial apoptosis, proliferation, EndMT. Pulmonary endothelium plays important roles in IPAH and several lines of evidence demonstrating EndMT formation and inflammation as contributing factors in the pathogenesis of IPAH.
This project aims at determining how and when endothelial remodeling contributes in process of IPAH and how that can be targeted in IPAH patients.
The Alfaidi Lab has received funding from the American Heart Association's Career Development Award for the years 2021-2024 for a total of $ 231,000. In addition, she received a seed package from the Center of Excellence for Cardiovascular Diseases and Science, Research Council and the LSU Health Shreveport Department of Internal Medicine.
Iqbal J, Chamberlain J, Alfaidi M, Hughes M, Alizadeh T, Casbolt H, Evans P, Mann B, Motterlini R, Francis S, Gunn J. Carbon monoxide releasing molecule a1 reduces myocardial damage after acute myocardial infarction in a porcine model. J Cardiovasc Pharmacol.31 May 2021. doi:10.1097/FJC.0000000000001067. PMID: 34328710.
Alfaidi M, Acosta CH, Wang D, Traylor JG, Orr AW. Selective role of nck1 in atherogenic inflammation and plaque formation. J Clin Invest. 2020;130:4331-4347. PMID: 32427580.
Alfaidi M, Chamberlain J, Rothman A, Crossman D, Villa-Uriol MC, Hadoke P, Wu J, Schenkel T, Evans PC, Francis SE. Dietary docosahexaenoic acid reduces oscillatory wall shear stress, atherosclerosis, and hypertension, most likely mediated via an IL-1-mediated mechanism. J Am Heart Assoc. 2018;7 (13). PMID: 29960988.
Smith SA, Samokhin AO, Alfaidi M, Murphy EC, Rhodes D, Holcombe WML, Kiss-Toth E, Storey RF, Yee SP, Francis SE, Qwarnstrom EE. The IL-1RI Co-Receptor TILRR (FREM1 Isoform 2) Controls Aberrant Inflammatory Responses and Development of Vascular Disease. JACC Basic Transl Sci. 2017;2(4):398-414. PMID: 28920098
Alfaidi M, Wilson H, Daigneault M, Burnett A, Ridger V, Chamberlain J, Francis S. Neutrophil elastase promotes interleukin-1beta secretion from human coronary endothelium. J Biol Chem. 2015;290:24067-24078. PMID: 26269588.
Mabruka Alfaidi, MD, PhD
My research vision is to develop a cellular therapy targeted approach to treat ischemic heart disease patients.
Meleah’s project is on investigating the molecular mechanism of sickle cell disease vaso-occlusive crises.
Evan's project is on Endothelial- to-Mesenchymal Activation in CVD.
Shandrika is sponsored by AHA through the HBCUs program. Shandrika is interested in pulmonary endothelial activation.
Education & Training
Postdoctoral Fellows interested in conducting research in the Alfaidi Lab can contact Dr. Alfaidi at Mabruka.Alfaidi@lsuhs.edu.
Graduate students interested in conducting research in the Alfaidi Lab can contact Dr. Alfaidi at Mabruka.Alfaidi@lsuhs.edu.
Undergraduate Research Assistants
Undergraduate students interested in conducting research in the Alfaidi Lab can contact Dr. Alfaidi at Mabruka.Alfaidi@lsuhs.edu.
Medical Students, Residents, and Fellows
Students, residents and fellows interested in conducting research in the Alfaidi Lab can contact Dr. Alfaidi at Mabruka.Alfaidi@lsuhs.edu.
Department of Internal Medicine
Louisiana State University Health Shreveport
1501 Kings Highway, Shreveport LA 71103